Pacira Biosciences, Inc.

As of October 24, 2025, Pacira Biosciences, Inc. shows a neutral trend with mixed technical signals, underperforming the S&P 500 recently but outperforming it year-to-date and over the past year, suggesting a cautious investment approach.

As of October 24, 2025, Pacira Biosciences, Inc. shows a neutral trend with mixed signals, as the weekly MACD is bearish and Bollinger Bands indicate bearish conditions, while it has underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of October 24, 2025, Pacira Biosciences, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 recently but outperforming it year-to-date, indicating caution in the current market.

As of October 3, 2025, Pacira Biosciences, Inc. shows a mildly bullish trend overall, supported by monthly indicators, but tempered by weekly bearish signals, while it has outperformed the S&P 500 year-to-date and over the past year, despite negative longer-term returns.

As of October 3, 2025, Pacira Biosciences, Inc. shows a mildly bullish trend overall, supported by positive MACD and moving averages, but tempered by some bearish signals and recent underperformance compared to the S&P 500.

As of October 3, 2025, Pacira Biosciences, Inc. shows a mildly bullish trend with positive MACD and moving averages, despite mixed signals from Dow Theory and recent underperformance against the S&P 500.

As of September 8, 2025, Pacira Biosciences, Inc. shows a bullish trend with strong daily moving averages and a bullish weekly MACD, despite a bearish weekly RSI indicating short-term weakness, while the stock has significantly outperformed the S&P 500 over the past month and year.

As of November 6, 2024, Pacira Biosciences, Inc. is considered risky due to its overvaluation metrics compared to peers, despite a strong year-to-date stock performance, but it has significantly underperformed over the long term.

As of November 6, 2024, Pacira Biosciences, Inc. is considered overvalued with a P/E ratio of 19, higher than the peer average, and modest financial performance metrics, leading to a valuation grade shift from attractive to risky.

As of June 17, 2025, Pacira Biosciences, Inc. shows a mildly bullish trend based on daily moving averages and monthly MACD, despite mixed signals from weekly indicators and a lack of momentum in the RSI.

As of March 2022, the management team of Pacira Biosciences, Inc. includes David Stack as Chairman and CEO, Paul Hastings as Lead Independent Director, and independent directors Christopher Christie, Laura Brege, Mark Froimson, and Yvonne Greenstreet.

Pacira Biosciences, Inc. is a pharmaceutical company specializing in the development and commercialization of products using its DepoFoam extended release technology. As of March 2025, it reported net sales of $169 million and a market cap of approximately $1.13 billion.

As of Jun 18, Pacira Biosciences, Inc. has a market capitalization of 1,129.37 million, with net sales of 702.76 million and a net profit of -103.73 million over the latest four quarters. Shareholder's funds are at 778.35 million, and total assets amount to 1,553.52 million.